Kondroid Siringom
Özet
Kondroid siringom, tıp literatüründe derinin mikst tümörü olarak da adlandırılan, epitelyal, mezenkimal ve myoepitelyal komponentleri bir arada barındıran, hem apokrin hem de ekrin kökenli nadir ve genellikle benign bir deri eki tümörüdür. Tüm primer deri tümörleri arasındaki insidansı %0.01'den az olan bu neoplazm, kadınlara kıyasla erkeklerde belirgin şekilde daha sık ortaya çıkmaktadır. Klinik olarak çoğunlukla baş ve boyun bölgesinde yerleşen, yavaş büyüme eğilimi gösteren, ülsere olmayan, ağrısız, iyi sınırlı, subkutan ya da intradermal kitleler şeklinde gözlenir. Histopatolojik tanısında küboidal veya poligonal hücre adaları, çift tabakalı hücrelerle döşeli tübüloalveoler veya duktal yapılar ve miksoid ya da kondroid nitelikteki değişken matriks kompozisyonu temel mikroskobik kriterleri oluşturur. Lümen görünümlerine göre apokrin ve ekrin varyantları bulunan bu lezyonların kesin tanısı için eksize edilen dokunun histolojik incelenmesi esastır. İmmünhistokimyasal profillemede tübüllerin iç tabakası Sitokeratin ve CEA ile boyanırken, dış tabaka hücreleri S100 ve Vimentin pozitifliği gösterir. Tedavide esas yaklaşım total cerrahi eksizyon olup, tam çıkarılma sonrasında nüks izlenmez. Ancak, nadiren uzak organlara metastaz yapabilen, hızlı büyüyen, belirgin hücresel atipi ve nekroz içeren yüksek dereceli malign tipi de mevcuttur.
Chondroid syringoma, also widely designated as a mixed tumor of the skin, represents a rare and predominantly benign cutaneous adnexal neoplasm derived from both apocrine and eccrine origins, characteristically encompassing epithelial, mesenchymal, and myoepithelial components. Comprising less than 0.01% of all primary skin tumors, this condition exhibits a higher prevalence in male patients than in females. Clinically, it typically presents within the head and neck region as a slow-growing, non-ulcerated, painless, and well-circumscribed subcutaneous or intradermal nodule. Histopathologically, the definitive diagnosis is established based on key microscopic criteria, including islands of cuboidal or polygonal cells, ductal structures lined by single or double rows of cells, and a variable chondromyxoid matrix. Divided into apocrine and eccrine variants based on lumen features, immunohistochemical analysis shows that the inner epithelial layer is reactive for Cytokeratin and CEA, whereas the outer layer stains positive for S100 and Vimentin. The primary therapeutic management relies entirely on complete surgical excision, which carries an excellent prognosis with virtually no risk of recurrence. Nevertheless, an extremely rare malignant variant exists, characterized by rapid expansion, cytological atypia, necrosis, and high metastatic potential, requiring wide surgical resection and adjuvant oncological therapies.
Referanslar
Lebe B (2018). Deri Eki Tümörleri. Demirkesen C (Ed). Deri Tümörleri. (370-378) Ankara Nobel Tıp Kitabevleri
Awasthi R, Harmse D, Courtney D, et al. Benignmixedtumour of the skin withextensiveossificationandmarrowformation: a casereport . J ClinPathol. 2004;57:1329-1330.doi:10.1136/jcp.2004.020172
Sangüeza, O. P., Cassarino, D. S., Glusac, E. J. (2018). Mixed Tumour. In David E. Elder, DanielaMassi (Eds), WHO Classification of Skin Tumours (4nd ed., pp. 193). Lyon.
Purkayastha P, Thomson R, Jones N, et al. Chondroidsyringoma: an unusualpresentation in a 7-year-old boy : a casereport. BMJ Case Rep. 2021;14:e232943.doi:10.1136/bcr-2019-232943
Patterson J. (2012) CutaneousAppendagealTumors. InKevinO.Leslie, Mark R.Wick (Eds)
Park S, Kang S, Choi H, et al. Chondroidsyringoma of a cheek :acasereport. Journal of CraniofacialSurgery: 2017;28:480-481. Doi:10.1097/scs.0000000000003689
Paik Y, Liess B. Chondroidsyringoma of thescalp: a casereport. NoseandThroatJournal 2011;90:190-19.doi:10.1177/014556131109000411
Sirivella S, Gielchinsky I. ChondroidSyringoma: A RareTumor of theChest Wall. AnnThoracSurg 2010;983–985.doi:10.1016/j.athoracsur.2009.07.062
Yılmaz F,KöybaşıS,Gürel K. KondroidSiringom Elektronik Kulak Burun Boğaz ve Baş Boyun Cerrahisi Dergisi 2005,Cilt 4,Sayı 3
Calonje,E., Brenn,T.,Lazar,A. (2020). Tumors of TheSweatGlands. In Thomas Brenn, Alexander J.Lazar (Eds), MCKEE’S Pathology of The Skin (5nd ed., pp.1623-1630).
Plachta I, Kleibert M, Czarnecka A, et all. Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. Int J MolSci 2021; 5077.doi:10.3390/ijms22105077
SivamaniR,WadheraAkhil,Craig E. ChondroidSyringoma:acasereportandrewiew of the literatüre. Dermatology Online Journal 12 (5):8. Doi: 10.570/D32kg558r6
CinelL,MollamemişoğluH,Kombak F. Kondroid Siringom (Derinin Mikst Tümörü): Olgu Serisi ve Literatür Derlemesi. J CurrPatholl2019;1:31-34doi:10.5146/jcpath.2019.40
HoslerG,Prenshaw K.(2021) Tumors of Cutaneous Appendages. . InPatterson,JW (Eds). Weedon’s Skin Pathology (5nd ed,pp 997-998)
Akasaka T, Onodera H, Matsuma M. Cutaneous Mixed Tumor Containing Ossification, Hair Matrix, andSebaceous Ductal Differentiation. TheJournal of Dermatology1997;125-131.doi:10.1111/j.1346-8138.1997.tbo2757.x
Cassarino D, Dadras S, Lindberg M (2016) Cutaneous Mixed Tumor (ChondroidSyringoma) In Steven D.Billings (Eds), Diagnostic Pathology Neoplastic Dermatopathology (2nd ed.,pp.1038-1050).
Watarai A, Amoh Y, Aki R, et all. Malignant Chondroid Syringoma: a case report. Dermatology Online Journal 2017; 9.doi:10.5070/D30568f3qz
Panagopoulos I, Gorunova L, Lund-Iversen M, NDRG1-PLAG1 and TRPS1-PLAG1 FusionGenes in Chondroid Syringoma. Cancer Genomics&Proteomics 2020,17:237-248. doi:10.21873/cgp.20184
ArgenyiZB,BaloghK,GoekenJA. Immunohistochemical Characterization of Chondroid Syringomas.Am J ClinPathol 1988;90(6):662-9.doi:10.1093/ajcp/90.6.662.
Dominguez F, Fresno F, SolerS, Fernandez G, Herrero Z. ChondroidSyringoma:a histologicalandimmünhistochemicalstudy of 15 cases. Histopathology 1990, 17, 311-317. Doi:10.1111/j.1365-2559.1990.tb00734.x
Yavuzer R,BaşterziY,Sari A. Chondroid Syringoma: a diagnosismorefrequentthanexpected.Dermatol Surg.2003; 29(2):179-81.doi:10.1046/j.1524-4725.2003.29045.x
BatesW,Baithun S. Atypical Mixed Tumor of the Skin: Histologic, İmmunohistochemical and Ultrastructural Features In Three Cases and Rewiew of the Criteria for Malignancy .Am J Dermatopathol 1998,20(1):35-40. Doi:10.1097/00000372-00007
Berson A, Lilia M, Emery R, et all. RecurrentMalignantChondroidSyringoma of theFoot: a casereport. AmericanJournal of ClinicalOncology 2000; 227-232.doi:10.1097/00000421-200006000-00003
Picard C, Harou O, Perrefeu, et all. UnusualCysticLesion of theEyebrow: a casereport. J Stomatol Oral MaxillofacSurg 2018; 232-235.doi:10.1016/j.jormas.2018.02.008
TakahashiH,IshikoA,KobayashiM,Tanikawa A. MalignantChondroidSyringomawith Bone Invasion: ACase Report andRewiew of theLiterature.Am J Dermatopathol 2004,26;403-406.doi:10.1097/00000372-200410000-00011
Panagopoulos I, Gorunova L, Lund-Iversen M, Bassarova A. Fusion of theGenes PHF1 and TFE3 in MalignantChondroidSyringoma. CancerGenomics&Proteomics 2019,16:345-351.doi:10.21873/cgp.20139
Tural D, Selçukbiricik F, Günver F, et all. FacialLocalization of MalignantChondroidSyringoma: a casereport. OncologicalMedicine 2013; 3.doi:10.1155/2013/907980
Mishra K, AgarwalS.FineNeedleAspirationCytology of MalignantChondroidSyringoma: a casereport. The International Academy of Cytology 1998
MathiasenR,RasgonB,Rumore G. MalignantChondroidSyringoma of theFace: A First Reported Case. OtolaryngologyHeadandNeckSurgery (2005) 133,305-307.doi:10.1016/j.otohns.2004.09.139
SheikhS,PennanenM,Montgomery E. BenignChondroidSyringoma: report of a caseclinicallymimicking a malignantneoplasm. J SurgOncol 2000;73(4):228-30.doi:10.1002/(sici)1096-9098(200004)73:4<228::aid-jso8>3.0.co;2-m
Matz L, McCully D. MetastasizingChondroidSyringoma: a casereport. TheRoyalCollege of Pathologists of Australasia1969; 77-81.doi:10.1159/000332105
Malik R, Saxena A, Kamath N. A Rare Case of MalignantChondroidSyringoma of Scalp: a casereport. IndianDermatol Online J 2013; 236-238
Wan H, Xu M, Xia T. ClinicalandPathologicalStudy on Mixed Tumors of the Skin: a casereport. Medicine 2018; 122-126.doi:10.4103/2229-5178.115533
